Globeflex Capital L P Makes New $1.92 Million Investment in Collegium Pharmaceutical, Inc. $COLL

Globeflex Capital L P acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 2nd quarter, HoldingsChannel reports. The firm acquired 52,911 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,915,000.

Several other hedge funds also recently modified their holdings of COLL. Vanguard Group Inc. lifted its stake in Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after acquiring an additional 29,876 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $686,000. Louisiana State Employees Retirement System purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $463,000. Intech Investment Management LLC lifted its position in shares of Collegium Pharmaceutical by 25.5% during the fourth quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock valued at $5,040,000 after purchasing an additional 22,146 shares in the last quarter. Finally, Jackson Creek Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 263.9% during the fourth quarter. Jackson Creek Investment Advisors LLC now owns 38,846 shares of the specialty pharmaceutical company’s stock valued at $1,799,000 after purchasing an additional 28,170 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL opened at $27.35 on Tuesday. The company has a market capitalization of $890.52 million, a price-to-earnings ratio of 22.06 and a beta of 0.73. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The firm has a 50-day moving average price of $33.53 and a 200-day moving average price of $35.56. Collegium Pharmaceutical, Inc. has a twelve month low of $25.47 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. Collegium Pharmaceutical’s revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.68 EPS. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current year.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of recent analyst reports. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Needham & Company LLC reduced their target price on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.